Polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Receiving MIND diet with modified calorie for 2 months. In this group, the required energy of each person will be determined based on Mifflin-St Jeor formula, the r
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Patients with PCOS based on the Rotterdam diagnostic criteria Age range from 18 to 45 years old Desire to cooperate Body mass index equal to or higher than 25 kg/m2 No recent weight loss during the previous 3 months Failure to follow a specific diet
Exclusion criteria
Exclusion criteria: Having known metabolic diseases Having known neurological disease Having major systemic diseases such as malignancies Having known liver disease Taking Antidepressants or history of diagnosis of depression during the previous one year Taking medications that affect appetite and body weight, such as corticosteroids or other supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression score. Timepoint: Baseline and End-of-trial. Method of measurement: Depression Anxiety and Stress Scale-21 Questionnaire.;Anxiety score. Timepoint: Baseline and End-of-trial. Method of measurement: Depression Anxiety and Stress Scale-21 Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Glucose oxidase assay.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Chemiluminescence immunoassay (CLIA).;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Chemiluminescence immunoassay (CLIA).;Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Ferriman-Gallway scoring system.;Quality of life score. Timepoint: Baseline and End-of-trial. Method of measurement: Polycystic Ovary Syndrome Questionnaire.;Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Digital scale.;Body mass index. Timepoint: Baseline and End-of-trial. Method of measurement: Dividing weight (in kilograms) by the square of height (in meters).;Waist circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Tape measure.;Hip circumference. Timepoint: Baseline and End-of-trial. Method of measurement: Tape measure.;Waist to hip ratio. Timepoint: Baseline and End-of-trial. Method of measurement: Dividing waist circumference (in centimeters) by the hip circumference (in centimeters).;Systolic blood pressure. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJalal Moludi
Kermanshah University of Medical Sciences
Outcome results
None listed